It must be remarked that differently from the previously published cost-effectiveness studies [17,18], in our study only first-treatment cycles were considered, Hp-uFSH (and not u-FSH) was used, mainly normal (and not all PCOS) patients were included, and the delivery rate (and not just the clinical pregnancy rate) was considered as the best clinical outcome indicator. This evidence concerns the gene HP and polycystic ovary syndrome.